(Reuters) -High cost, logistical issues and the prospect of potential treatment advances are holding back adoption of the first gene therapies for hemophilia, experts said this week during the ...

Sanofi announced Sunday that Altuviiio, its hemophilia treatment, is effective and safe, according to recently released Phase 3 trial data. The study, which focused on treating patients younger than ...

Steven W. Pipe, MD, shares insights on optimizing hemophilia treatment schedules and minimizing hoarding of factor VIII prophylaxis or emicizumab for improved patient adherence. This is a video ...

Hemophilia is a rare and often misunderstood disease. Many people only know that it’s a blood disorder, and after that, myths and misinformation abound. So what exactly is hemophilia? Alisa Wolberg, ...

Allison Wheeler, MD, explores the transformative journey of hemophilia A treatment, from blood products to advanced recombinant factor therapies, longer half-life products, and subcutaneous injections ...

Hemophilia is a complex disease that requires care from medical providers who are experienced in treating it. The symptoms of hemophilia — bleeding and bruising — are caused by having a low level of ...

Researchers may have found a way for people with severe hemophilia to take their standard treatment less often, if the results of an early trial pan out. In what experts called a feat of ...

Families of children with severe hemophilia A may want to take a fresh look at treatment options from human plasma. A study published in the New England Journal of Medicine on May 26 showed that ...

ATLANTA, Georgia — It's a problem many clinicians would love to have: a whole variety of new or emerging therapeutic options to use in the care of their patients. In a session titled "Hemophilia ...

Hemophilia A is a rare, inherited condition that prevents your blood from clotting the way it should. People with hemophilia A do not make enough of a protein called factor VIII, which normally works ...